Remdesivir is an RNA polymerase inhibitor. Clinical trials have shown that the medication has reversible hepatotoxicity and linear pharmacokinetics. Its metabolism has not been fully studied. However, as a substrate of CYP3A4 it is likely that there could be a decrease in remdesivir elimination due to the downregulation of CYP3A4 by inflammatory mediators. With the dosing schedule of remdesivir in COVID-19 patients there is a risk of an unpredictable dose-toxicity relationship and nonlinear pharmacokinetics due to the implementation of a loading dose followed up by infusions. The pharmacokinetics of the drug becomes dose dependent. Favipiravir is also an RNA polymerase inhibitor but, unlike remdesivir, it is not metabolized by CYP enzymes and no significant effect on the disposition of COVID-19 patients is expected at this time.